EP Patent

EP0114589A1 — Inhibition of angiogenesis

Assigned to Harvard University · Expires 1984-08-01 · 42y expired

What this patent protects

Angiogenesis in mammals is inhibited by administration of heparin or a heparin fragment which is a hexasaccharide or larger together with cortisone, hydrocortisone or the 11- alpha isomer of hydrocortisone. Inhibition of tumor-induced angiogenesis is accompanied by tumor regressi…

USPTO Abstract

Angiogenesis in mammals is inhibited by administration of heparin or a heparin fragment which is a hexasaccharide or larger together with cortisone, hydrocortisone or the 11- alpha isomer of hydrocortisone. Inhibition of tumor-induced angiogenesis is accompanied by tumor regression, and prevention of metastasis.

Drugs covered by this patent

Patent Metadata

Patent number
EP0114589A1
Jurisdiction
EP
Classification
—
Expires
1984-08-01
Drug substance claim
No
Drug product claim
No
Assignee
Harvard University
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.